NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

Key Takeaways Novartis lifted its 2024-2029 sales outlook to 6% and projects 5-6% annual growth through 2030.Stronger guidance reflects momentum from key drugs and recent launches despite U.S. generics.Kisqali and Scemblix saw sharp third-quarter sales jumps, prompting higher peak-sales forecasts.Novartis (NVS) recently held an investor event, wherein management projected sales to grow at a compounded annual growth rate (CAGR) of 5-6% (at constant currencies) for 2025-2030.Management also upgraded its sales ...